Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Abhijeet Waghray

Internal Medicine Boston, MA Medical Doctor

NPI 1073878351 CMS profile 1948896

800 Washington St, Boston, MA 02111

Open in the dashboard

General payments

$13,087

563 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Abhijeet Waghray of Boston, MA is reported in the CMS Open Payments database as having received $13,087 across 563 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $161 2
2023 General $2,533 134
2022 General $4,409 187
2021 General $3,890 161
2020 General $1,160 61
2019 General $935 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abhijeet Waghray
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Abhijeet Waghray were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Abhijeet Waghray Internal Medicine median Middle half National median
2019 $935 $159 $48–$570 $163
2020 $1,160 $119 $33–$402 $114
2021 $3,890 $135 $37–$521 $132
2022 $4,409 $141 $42–$496 $149
2023 $2,533 $149 $45–$519 $160
2024 $161 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $3,788 133 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $3,002 196 payments
  3. E.R. Squibb & Sons, L.L.C. $1,123 10 payments
  4. Janssen Biotech, Inc. $598 24 payments
  5. RedHill Biopharma Inc. $571 34 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $556 37 payments
  7. Ferring Pharmaceuticals Inc. $471 15 payments
  8. QOL Medical, LLC $417 15 payments
  9. Pfizer Inc. $355 14 payments
  10. Regeneron Healthcare Solutions, Inc. $345 12 payments
  11. Other $1,860 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $12,886 560 payments
  2. Education $178 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23 1 payment
Products named General payments · program years 2019–2024
  1. XIFAXAN $1,584 104 payments
  2. ZEPOSIA $1,359 26 payments
  3. HUMIRA $1,274 51 payments
  4. TRULANCE $1,238 69 payments
  5. SKYRIZI $1,015 38 payments
  6. STELARA $719 25 payments
  7. Talicia $507 29 payments
  8. XELJANZ $355 14 payments
  9. LINZESS $348 28 payments
  10. DUPIXENT $345 12 payments
  11. Other $3,954 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

112

Median for Internal Medicine: 777

Drug cost

$1,631

Median for Internal Medicine: $73,373

Branded share of claims

58%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 39 $704
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 26 $537
Omeprazole Generic 47 $390

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$22,341

Medicare's payments for the services billed

Medicare patients

136

Average age 70

Services billed

216

81 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 46%
Diabetes 39%
Depression 22%
Chronic kidney disease 20%
COPD 17%
Ischemic heart disease 15%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

563 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record